Initial PC14586 Phase 1 data presented at the American Society of Clinical Oncology Annual Meeting demonstrated responses in patients across multiple solid tumor types with a p53 Y220C. | August 9, 2022
Published: Apr 14, 2021
Jeffrey Wasserman, JD, named General Counsel
WALTHAM, Mass. (BUSINESS WIRE) Pyramid Biosciences, Inc., a Boston-based, clinical-stage biotechnology company focused on developing new and highly differentiated precision therapies for cancer and other serious diseases, today announced two new appointments to the leadership team.
Brian Lestini, MD, PhD, has joined the company as Chief Medical Officer, where he will oversee the advancement and expansion of the Company s clinical pipeline. Dr. Lestini joins the Company from Bristol-Myers Squibb (NYSE: BMY), where he most recently was Vice President and Development Leader for the relatlimab (anti-LAG3) checkpoint inhibitor program. In this capacity, Dr. Lestini oversaw the development and commercialization strategy for this novel immune-oncology agent across a wide range of tumors. Dr. Lestini brings over a decade of early- and late-stage clinical development leadership experience in Oncology, includ
(1)
Results presented at the 2020 San Antonio Breast Cancer Symposium confirm the relevance of screening for HER2+ CTCs from blood samples in patients with a HER2 negative primary tumor biopsy to optimize treatment strategy and patient outcome
BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., Dec. 10, 2020 /PRNewswire/ Menarini Silicon Biosystems, a pioneer of liquid biopsy technology, announced today new data from the DETECT study program. These data focused on women with HER2 negative metastatic breast cancer (MBC) based on primary tumor biopsy, and HER2
+ CTCs. The results of this large program demonstrate that screening for HER2+ CTCs, in the blood samples of these patients, is an important tool to guide therapy decisions and improve patient outcomes. Furthermore, the randomized DETECT III phase III study, discussed in a poster spotlight session during the 2020 San Antonio Breast Cancer Symposium, shows that adding reference HER2 targeted TKI (tyrosine kinase inhibitor) lapatinib t
DETECT program studies validate clinical relevance of CTC HER2 phenotypes in metastatic breast cancer patients with HER2 negative primary tumor a | ANP Pers Support perssupport.nl - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from perssupport.nl Daily Mail and Mail on Sunday newspapers.